Article
Biochemistry & Molecular Biology
William G. J. Kerrison, Alexander T. J. Lee, Khin Thway, Robin L. Jones, Paul H. Huang
Summary: Immunotherapy in soft tissue sarcoma has become a popular and promising therapeutic strategy, with immune checkpoint inhibitors showing effectiveness in certain subtypes. Combination therapies have also shown enhanced response rates.
Article
Oncology
Do Weon Lee, Han-Soo Kim, Ilkyu Han
Summary: The study found that actual 5-year survival in stage III soft tissue sarcoma patients is associated with tumor size, histological grade, and ASA score. Nevertheless, the majority of long-term survivors still exhibit factors of poor prognosis.
Review
Pharmacology & Pharmacy
Tomoki Nakamura, Akihiro Sudo
Summary: Trabectedin is a safe and effective therapeutic option for patients with advanced STS. While it may be effective as first-line treatment in selected patients, doxorubicin remains the preferred choice for locally advanced or metastatic STS.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Tom Wei-Wu Chen, Ruru Chun-Ju Chiang, Alex Le Cesne, Yu-Chun Hsieh, Antoine Italiano, Ya-Wen Yang, Nicolas Penel, Wen-Chung Lee, Emmanuelle Bompas, Thibaud Valentin, Philippe Anract, Nelly Firmin, Florence Duffaud, Ann-Lii Cheng, Francoise Ducimetiere, K. Arnold Chan, Jean-Yves Blay
Summary: The study found significant differences in the incidence and clinical characteristics of soft tissue sarcoma (STS) among different geographic and ethnic populations, suggesting that geographic and ethnic factors may play a crucial role in the pathogenesis of STS.
Article
Biochemistry & Molecular Biology
Timur I. Fetisov, Sofya A. Khazanova, Polina A. Shtompel, Ekaterina S. Trapeznikova, Victoria Y. Zinovieva, Valeria I. Marshall, Anastasia A. Lovenger, Dmitriy V. Rogozhin, Tararykova A. Anastasia, Beniamin Yu. Bokhyan, Gennady A. Belitsky, Marianna G. Yakubovskaya, Kirill I. Kirsanov
Summary: Treatment of highly malignant soft tissue sarcomas (STSs) involves multicomponent therapy, but personalized selection of chemotherapy is lacking. In this study, in vitro chemosensitivity/resistance assays (CSRAs) were used to predict STS chemoresistance. Results showed that certain cancer histotypes had higher resistance to specific drugs and combinations, and the CSRAs were correlated with clinical responses and survival outcomes. CSRAs can assist physicians in avoiding ineffective treatments and aid researchers in developing new STS drugs.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Mauro Loi, Giulia Salvatore, Michele Aquilano, Daniela Greto, Cinzia Talamonti, Viola Salvestrini, Maria Elena Melica, Marianna Valzano, Giulio Francolini, Mariangela Sottili, Costanza Santini, Carlotta Becherini, Domenico Andrea Campanacci, Monica Mangoni, Lorenzo Livi
Summary: Trabectedin sensitizes STS cells to radiation therapy by reducing cell survival rate, inhibiting invasiveness, altering cell cycle distribution, and increasing γ-H2AX foci formation. However, it does not have a synergistic effect on DNA damage repair, neoangiogenesis, and the immune system.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Ahmet Bilici, Sinan Koca, Mustafa Karaagac, Sabin Goktas Aydin, Emrah Eraslan, Muhammed Ali Kaplan, Birol Ocak, Sema Sezgin Goksu, Semra Paydas, Fahri Akgul, Sumeyye Derin, Yakup Ergun, Emre Yekeduz, Cihan Erol, Deniz Tataroglu Ozyukseler, Atike Gokcen Demiray, Mustafa Karaca, Zeynep Gulsum Guc, Serkan Menekse, Havva Yesil Cinkir, Ozge Gumusay, Abdullah Sakin, Ozlem Ozkul, Hacer Demir, Dilek Erdem, Mehmet Besiroglu, Olcun Umit Unal, Ramazan Acar, Lokman Koral, Suleyman Sahin, Teoman Sakalar, Aykut Bahceci, Ahmet Ozveren, Ulug Mutlu Gunaydin, Mehmet Metin Seker, Veli Sunar, Pinar Dal, Mehmet Artac, Serdar Turhal
Summary: This study retrospectively analyzed the medical records of patients with non-adipocytic metastatic soft tissue sarcoma treated with pazopanib in 37 oncology clinics in Turkey. The results showed that pazopanib is effective and well-tolerated in the treatment of this disease, with better outcomes observed when used earlier and in patients with good performance status.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Immunology
Kayla L. Marritt, Karys M. Hildebrand, Kurt N. Hildebrand, Arvind K. Singla, Franz J. Zemp, Douglas J. Mahoney, Frank R. Jirik, Michael J. Monument
Summary: This study assessed the therapeutic response of intratumoral STING activation in an immunologically cold murine model of undifferentiated pleomorphic sarcoma (UPS). The results showed that a single intratumoral injection of the murine STING agonist resulted in durable cure in up to 60% of UPS-bearing mice. In mice with synchronous lung metastases, STING activation within hindlimb tumors also resulted in 50% cure in both anatomic sites.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Alessandra Buja, Massimo Rugge, Matteo Barillaro, Andrea Miatton, Saveria Tropea, Claudia Cozzolino, Manuel Zorzi, Antonella Vecchiato, Paolo Del Fiore, Antonella Brunello, Vincenzo Baldo, Carlo Riccardo Rossi, Simone Mocellin
Summary: This study aimed to compare the pathological and clinical features of retroperitoneal soft-tissue sarcomas (RPS) and non-RPS, and analyze if the hazard ratio for short-term mortality differs between RPS and non-RPS after adjusting for baseline differences. The analysis found that RPS accounted for 22.8% of cases, with different characteristics compared to non-RPS. The retroperitoneum site was an independent prognostic factor associated with worse overall survival in sarcoma patients.
Review
Oncology
P. D. Rowell, P. C. Ferguson, K. M. Tsoi, J. L. Nevin, R. Novak, A. M. Griffin, J. S. Wunder
Summary: This study reviewed the surgical and oncological outcomes of 29 patients with soft tissue sarcoma who underwent bone resection and endoprosthetic reconstruction (EPR) in the lower extremity. It found a high rate of complications associated with this procedure, including infections and reduced overall survival.
JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Matthew F. Gong, William T. Li, Sumail Bhogal, Brittany Royes, Tanya Heim, Maria Silvaggio, Marcus Malek, Rajeev Dhupar, Stella J. Lee, Richard L. McGough, Kurt R. Weiss
Summary: Soft tissue sarcomas (STS) are rare malignant tumors associated with poor outcomes and high local recurrence rates. Indocyanine green (ICG) has shown efficacy for intraoperative margin assessment in breast and gastrointestinal cancers. This study presents an ongoing clinical study implementing ICG intraoperative margin assessment in patients with STS. ICG margins matched permanent pathology margins in 56% of patients, with 22% sensitivity and 89% specificity. Larger sample sizes are needed to further evaluate the optimal dosage, timing, and impact on different histological subtypes of STS.
Article
Multidisciplinary Sciences
Luiza Ohasi de Figueiredo, Augusto Afonso Guerra Junior, Francisco de Assis Acurcio, Alessandra Maciel Almeida, Mariangela Leal Cherchiglia, Alberto Julius Alves Wainstein, Luiz Claudio Santos Thuler, Angelica Nogueira-Rodrigues
Summary: Brazil lacks comprehensive statistics on soft tissue sarcomas (STS), making it difficult to understand the epidemiological profile and clinical outcomes of patients. This study aimed to bridge this gap by analyzing data from a large cohort of STS patients in the Brazilian public health system. The majority of patients received surgical treatment, and a significant proportion of them resided in the Northeast region of Brazil. The 1-, 5- and 10-year survival rates were 75.4%, 43.4%, and 18.6% respectively.
SCIENTIFIC REPORTS
(2021)
Review
Oncology
Maria L. Inchaustegui, Kelly Kon-Liao, Kim Ruiz-Arellanos, George Aquilino E. Silva, Marcos R. Gonzalez, Juan Pretell-Mazzini
Summary: This systematic review analyzed the treatment options and outcomes for patients with radiation-induced soft tissue sarcomas (RISs). The most common treatment for RISs was surgery, with chemotherapy and radiotherapy used less frequently. Patients with RISs had a low 5-year survival rate, and high rates of local recurrence and cancer spreading.
Article
Oncology
Chiara Giraudo, Reineke Schoot, Liesbeth Cardoen, Roberto Stramare, Beatrice Coppadoro, Gianni Bisogno, Amine Bouhamama, Bernadette Brennan, Herve J. Brisse, Daniel Orbach, Ana Coma, Pier Luigi Di Paolo, Cindy Fayard, Leigh McDonald, Salma Moalla, Carlo Morosi, Erika Pace, Vivian Tang, Max M. van Noesel, Andrea Ferrari, Rick van Rijn
Summary: This study indicates that the presence of indeterminate pulmonary nodules does not significantly affect the survival of nonmetastatic patients with adult-type non-rhabdomyosarcoma soft tissue sarcoma (NRSTS).
Review
Biochemistry & Molecular Biology
Joon Hyuk Choi, Jae Y. Ro
Summary: Soft tissue tumors are rare mesenchymal tumors with diverse differentiation. They are challenging to diagnose due to the variety of tumor types and histological overlap. Advances in molecular genetic techniques and the development of immunohistochemical markers have improved our understanding of the molecular pathogenesis of soft tissue tumors. This review provides updated information on recent molecular findings and novel immunohistochemical markers in selected soft tissue tumors.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Alamelu Nachiyappan, Joshua Ling Jun Soon, Huey Jin Lim, Victor K. M. Lee, Reshma Taneja
Summary: The expression of EHMT1 is closely associated with the maintenance of tumor stemness in ARMS. Inhibition of EHMT1 activity reduces the motility of ARMS cells, induces differentiation, slows down tumor progression, and reduces tumorsphere formation. Targeting ALDH1A1 expression and activity may be a promising strategy for the treatment of ARMS.
JOURNAL OF PATHOLOGY
(2022)
Article
Oncology
Jin-Fen Xiao, Ley-Fang Kua, Ling-Wen Ding, Qiao-Yang Sun, Khine Nyein Myint, Xiu-Rong Chia, Nachiyappan Venkatachalam, Xinyi Loh, Jason E. Duex, Vanessa Neang, Siqin Zhou, Ying Li, Henry Yang, H. Phillip Koeffler, Dan Theodorescu
Summary: KDM6A depletion promotes cell migration and transformation in breast cells, reduces sensitivity to therapeutic agents, induces TGF beta secretion, and suppresses cytotoxic gene expression. KDM6A deficiency and TGF beta treatment drive tumor progression, leading to disorganized acinar structures and expression profiles associated with epithelial-to-mesenchymal transition and metastasis.
MOLECULAR CANCER RESEARCH
(2022)
Letter
Pathology
Noorjehan Omar, Muhd Afif Mohd Yusof, Victor Lee Kwan Min, Ikmal Hisyam Bakrin, Mazlina Awang, Fairos Abdul Muthalib
Article
Biochemistry & Molecular Biology
Hui Min Tan, He Cheng, Yew Chung Tang, Sai Mun Leong, Poh Yin Teo, Chi Kuen Lee, Victor Kwan Min Lee, Susan Swee-Shan Hue
Summary: Adipocytic tumors are the most common subtype of soft tissue tumors. Distinguishing benign lipomas from well-differentiated liposarcomas (WDLPS) and dedifferentiated liposarcomas (DDLPS) from their morphologic mimics remains challenging. This study identified miRNA-based signatures that can aid in the differential diagnosis of these tumors. These miRNAs were found to be involved in adipocytic cancer-related biological processes and pathways, supporting their potential use as biomarkers for adipocytic tumors.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Cell Biology
Daniel Xin Zhang, Xuan T. T. Dang, Luyen Tien Vu, Claudine Ming Hui Lim, Eric Yew Meng Yeo, Brenda Wan Shing Lam, Sai Mun Leong, Noorjehan Omar, Thomas Choudary Putti, Yu Chen Yeh, Victor Ma, Jia-Yuan Luo, William C. Cho, Gang Chen, Victor Kwan Min Lee, Andrew Grimson, Minh T. N. Le
Summary: Breast cancer cells release extracellular vesicles (EVs) that contain a large amount of biocargo, promoting intercellular communication and metastasis. It has been found that highly metastatic breast cancer cells have a higher enrichment of integrins, particularly alpha v and beta 1 subunits, in their EVs compared to poorly metastatic cells. Integrin alpha v has also been associated with disease progression in breast cancer patients. The export of integrin alpha v beta 1 into EVs is facilitated by members of the galectin family. Inhibition of the integrin alpha v beta 1 complex reduces the binding of EVs to fibronectin and decreases the metastatic potential of breast cancer cells.
JOURNAL OF EXTRACELLULAR VESICLES
(2022)
Article
Chemistry, Multidisciplinary
Pei Huang, Lingsheng Jiang, Hui Pan, Lingwen Ding, Bo Zhou, Mengyao Zhao, Jianhua Zou, Benhao Li, Meiwei Qi, Hongzhang Deng, Yongfeng Zhou, Xiaoyuan Chen
Summary: Researchers synthesized a new polymer for mRNA delivery, which showed no inflammatory side effects in vivo and successfully delivered mRNA cancer vaccines, resulting in robust anti-tumor cellular immune response.
ADVANCED MATERIALS
(2023)
Article
Oncology
Xue-Bin Ran, Ling-Wen Ding, Qiao-Yang Sun, Henry Yang, Jonathan W. Said, Lao Zhentang, Vikas Madan, Pushkar Dakle, Jin-Fen Xiao, Xinyi Loh, Ying Li, Liang Xu, Xiao-Qiang Xiang, Ling-Zhi Wang, Boon Cher Goh, De-Chen Lin, Wee Joo Chng, Soo-Yong Tan, Sudhakar Jha, H. Phillip Koeffler
Summary: Despite the limited response rate of immune checkpoint blockade therapy, targeting RNA decay machinery by silencing XRN1 can sensitize tumor cells to immunotherapy by activating IFN signaling and the viral defense pathway. XRN1 depletion triggers aberrant RNA-mediated IFN signaling and has the potential to be effective in multiple types of cancers. These findings provide a molecular rationale for developing XRN1 inhibitors and combining them with cancer immunotherapy.
Article
Medicine, Research & Experimental
Win Lwin Thuya, Li Ren Kong, Nicholas L. Syn, Ling -Wen Ding, Esther Sok Hwee Cheow, Regina Tong Xin Wong, Tingting Wang, Robby Miguel Wen-Jing Goh, Hongyan Song, Migara K. Jayasinghe, Minh T. N. Le, Jian Cheng Hu, Wei-Peng Yong, Soo-Chin Lee, Andrea Li-Ann Wong, Gautam Sethi, Huynh The Hung, Paul Chi-Lui Ho, Jean-Paul Thiery, Siu Kwan Sze, Tiannan Guo, Ross A. Soo, Henry Yang, Yaw Chyn Lim, Lingzhi Wang, Boon-Cher Goh
Summary: This study reveals that the cargo protein FAM3C carried by tumor-released extracellular vesicles (EVs) can enhance the growth and metastatic potential of lung cancer cells. FAM3C interacts with RalA protein to activate the Src/Stat3 signaling pathway, promoting oncogenicity. This finding provides a new target for lung cancer therapy.
Article
Biochemistry & Molecular Biology
Kenon Chua, Arthur Yi Loong Sim, Eric Yew Meng Yeo, Muhammad Sufyan Bin Masroni, Wah Wah Naw, Sai Mun Leong, Kee Wah Lee, Huey Jin Lim, David M. Virshup, Victor Kwan Min Lee
Summary: There is an urgency to find new drugs for high-grade cancers like osteosarcomas, as current therapeutic options are limited. A PORCN inhibitor called ETC-159 has shown promise in clinical trials by inhibiting Wnt, a key driver in these tumors. In vivo and in vitro models demonstrated that ETC-159 reduces beta-catenin staining, increases tumor necrosis, and reduces vascularity, indicating a potential new treatment approach for osteosarcomas.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Pathology
Naw Wah Wah, Yingting Mok, Noorjehan Omar, Kenneth Tou En Chang, Timothy Kwan Yong Tay, Susan Swee-Shan Hue, Victor Kwan Min Lee
Summary: This study characterized copy number alterations in EBV-SMTs and compared them with leiomyomas and leiomyosarcomas. The results showed a lower copy number alteration burden in EBV-SMTs and leiomyomas compared to leiomyosarcomas. Additionally, recurrent copy number gain of oncogenes was found in EBV-SMTs.
Article
Biochemical Research Methods
Joana Rita Oliveira Faria Marques, Patricia Gonzalez-Alva, Ruby Yu-Tong Lin, Beatriz Ferreira Fernandes, Akhilanand Chaurasia, Nileshkumar Dubey
Summary: Cancer treatment development is complex due to tumor heterogeneity and inter-patient variations. Traditional 2D cell culture is insufficient to mimic tumor-specific architecture, while 3D culture techniques and bioprinting have shown promise in bridging the gap.
Article
Oncology
Guo Yuan How, Chik Hong Kuick, Min Hwee Yong, Shui Yen Soh, Esther X. Y. Hee, Meng Kang Wong, Richard Quek, Mohd Farid Harunal, Sathiyamoorthy Selvarajan, Kesavan Sittampalam, Chetan Anil Dhamne, Victor Lee, Kenneth T. E. Chang, Amos H. P. Loh
Summary: This study conducted a retrospective population-based study on 67 rhabdomyosarcoma patients in Singapore public hospitals from 2004 to 2014, and found significant clinical differences among different age groups and molecular subtypes. The results showed higher prevalence of embryonal and alveolar tumors among children. Older age was associated with different treatment responses and survival outcomes. Overall survival was influenced by stage, group, and surgical resection. The subtypes of rhabdomyosarcoma exhibited significant variation between adults and children, especially in terms of surgical resectability.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Gideon Ze Lin Tan, Sai Mun Leong, Yu Jin, Chik Hong Kuick, Jeremy Joon Keat Chee, San Zeng Low, Ling-Wen Ding, He Cheng, Diana Lim, Susan Swee-Shan Hue
Summary: In this study, we analyzed the expression of microRNAs in endometrial carcinomas and found differential expression profiles among different subtypes and molecular subtypes. These findings may have implications for the development of diagnostic and prognostic tools for endometrial carcinoma.
Letter
Urology & Nephrology
Ren Wei Liu, Gideon Tan, Yi Ting Lim, Wei Jin Chua, Amanda Cheng, Ying Mei Wong, Victor Lee, Thomas Thamboo
ASIAN JOURNAL OF UROLOGY
(2023)
Review
Oncology
Oswald Zhao Jian Lee, Noorjehan Omar, Joshua K. Tay, Victor Kwan Min Lee
Summary: This review provides a comprehensive overview of Epstein-Barr virus-associated mesenchymal tumors, including their clinical features, pathological characteristics, pathophysiology, prognostic factors, and current treatment approaches. Through an extensive literature search, three distinct EBV-associated mesenchymal tumors were identified: EBV-associated smooth muscle tumors, inflammatory pseudotumor-like follicular dendritic cell sarcomas, and EBV-associated osteosarcomas. Although there is still incomplete understanding of the underlying pathophysiology, this review aims to serve as a catalyst for further research to bridge the knowledge gap and contribute to future therapeutic approaches.